2023 Fiscal Year Final Research Report

Comprehensive cancer-related pathway analysis of genetic abnormalities in HER2-positive gallbladder cancer and their clinical significance

Research Project

PDF

Project/Area Number	21K08770
Research Category	Grant-in-Aid for Scientific Research (C)
Allocation Type	Multi-year Fund
Section	一般
Review Section	Basic Section 55020:Digestive surgery-related
Research Institution	Niigata University
Principal Investigator	Sakata Jun 新潟大学, 医歯学系, 准教授 (70447605)
Co-Investigator(Kenkyū-buntansha)	若井俊文新潟大学, 医歯学系, 教授 (50372470) 島田能史新潟大学, 医歯学系, 講師 (20706460) 滝沢一泰新潟大学, 医歯学総合病院, 講師 (30706437) 市川寛新潟大学, 医歯学系, 助教 (50721875) 三浦宏平新潟大学, 医歯学総合病院, 特任助教 (70733658) 諸和樹新潟大学, 医歯学総合病院, 助教 (10745566) 永橋昌幸新潟大学, 医歯学総合研究科, 客員研究員 (30743918) 石川博補新潟大学, 医歯学総合病院, 助教 (80769399)
Project Period (FY)	2021-04-01 – 2024-03-31
Keywords	HER2陽性胆嚢癌 / 抗HER2療法 / 免疫組織化学 / FISH / 外科切除 / 生存解析
Outline of Final Research Achievements	This study aimed to identify the frequency of positive HER2 tests and to investigate the association between HER2 positivity and clinicopathological factors in patients with resectable gallbladder cancer. Data of 45 patients with gallbladder cancer who underwent surgery with curative intent were reviewed. Surgically resected specimens were evaluated for HER2 expression/ERBB2 amplification by immunohistochemistry and fluorescence in situ hybridization, respectively. Of these 45 patients, 5 (11.1%) had a positive HER2 test. Positive HER2 test was not associated with the extent of tumor spread, histological type and grade, or overall survival. The 5-year overall survival rates in HER2-positive (n = 5) and HER2-negative (n = 40) patients were 80.0% and 51.2%, respectively (p=0.283). Further studies to investigate the clinical effects of anti-HER2 therapy for HER2-positive gallbladder cancer is warranted.
Free Research Field	消化器外科
Academic Significance and Societal Importance of the Research Achievements	胆嚢癌は生物学的悪性度の高い癌の一つであり，予後不良の胆嚢癌の治療成績向上のためには，新規治療薬導入を含めた集学的治療の進歩が必要不可欠である．胆嚢癌で最も高率に検出される遺伝子異常の一つにERBB2遺伝子の増幅があり，HER2タンパク質過剰発現（HER2陽性）を呈する．そのような胆嚢癌に対する抗HER2療法の高い治療効果が報告されている。本研究は，HER2陽性胆嚢癌に対する抗HER2療法を基軸とした胆嚢癌薬物療法発展の足がかりとなると考えられる。